Kristin Morris
About
Kristin Morris is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Kristin Morris has authored 24 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kristin Morris's work include CAR-T cell therapy research (7 papers), Cancer Research and Treatments (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Kristin Morris is often cited by papers focused on CAR-T cell therapy research (7 papers), Cancer Research and Treatments (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Kristin Morris collaborates with scholars based in United States, Australia and Greece. Kristin Morris's co-authors include Edward D. Chan, David W. H. Riches, Preston J. Hill, John M. Routes, Patrick J. Brennan, Linda K. Remigio, Sharon Ryan, John T. Belisle, Kathryn Chmura and Tetsu Kamitani and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Kristin Morris
23 papers receiving 449 citations
Peers
Kristin Morris
Laura Visconti Italy
Ulf Alexander Wenzel Sweden
Marcel Doerflinger Australia
Parul Mehra India
Erin Bailey United States
Yajing Gao United States
Libin Chen China
Xiaojie Yan China
Shahzada Khan United States
Diana L. Bonilla United States
Citations per year, relative to Kristin Morris Kristin Morris (= 1×)
peers
Laura Visconti
Countries citing papers authored by Kristin Morris
Since
Specialization
Citations
This map shows the geographic impact of Kristin Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristin Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristin Morris more than expected).
Fields of papers citing papers by Kristin Morris
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kristin Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristin Morris. The network helps show where Kristin Morris may publish in the future.
Co-authorship network of co-authors of Kristin Morris
This figure shows the co-authorship network connecting the top 25 collaborators of Kristin Morris. A scholar is included among the top collaborators of Kristin Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kristin Morris. Kristin Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Trudel, Suzanne, Meral Beksaç, Luděk Pour, et al.. (2025). DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features.. Journal of Clinical Oncology. 43(16_suppl). 7533–7533.
2.
Moser, Justin C., Mateusz Opyrchal, Brendan D. Curti, et al.. (2024). A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2623–2623.
3.
Trudel, Suzanne, Meral Beksaç, Luděk Pour, et al.. (2024). Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(17_suppl). LBA105–LBA105.
4.
Morris, Kristin, Daniel J. Hicklin, Christopher J. Nirschl, et al.. (2024). Abstract 4074: Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models. Cancer Research. 84(6_Supplement). 4074–4074.
5.
Moser, Justin C., Mateusz Opyrchal, Mehmet Asım Bilen, et al.. (2023). 737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors. SHILAP Revista de lepidopterología. A830–A830.
6.
Tyagi, Ethika, Dan Hicklin, Nesreen S. Ismail, et al.. (2021). 723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models. SHILAP Revista de lepidopterología. A752–A752.
7.
Steiner, Philipp, Dan Hicklin, Nesreen S. Ismail, et al.. (2021). Abstract 1716: WTX-330, a conditionally activated IL-12 INDUKINE, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models. Cancer Research. 81(13_Supplement). 1716–1716.
8.
Steiner, Philipp, Daniel J. Hicklin, Randi Isaacs, et al.. (2021). Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates. Blood. 138(Supplement 1). 2258–2258.
9.
Morris, Kristin, Daniel J. Hicklin, Nesreen S. Ismail, et al.. (2021). 715 WTX-330 is an IL-12 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models. SHILAP Revista de lepidopterología. A744–A744.
10.
Salmerón, Andrés, Daniel J. Hicklin, Nesreen S. Ismail, et al.. (2021). Abstract 1723: WTX-124 is an IL-2 pro-drug conditionally activated in tumors and able to induce complete regressions in mouse tumor models. Cancer Research. 81(13_Supplement). 1723–1723.
11.
Jacobs, Peter G., Nichole S. Tyler, Scott M. Vanderwerf, et al.. (2020). Measuring glucose at the site of insulin delivery with a redox-mediated sensor. Biosensors and Bioelectronics. 165. 112221–112221.
12.
Ward, W. Kenneth, Kristin Morris, Scott E. Campbell, et al.. (2017). An Amperometric Glucose Sensor Integrated into an Insulin Delivery Cannula: In Vitro and In Vivo Evaluation. Diabetes Technology & Therapeutics. 19(4). 226–236.
13.
Morris, Kristin, et al.. (2009). Suppression of IFNγ+mycobacterial lipoarabinomannan-induced NO by IL-4 is due to decreased IRF-1 expression. Tuberculosis. 89(4). 294–303.
14.
Routes, John M., Sharon Ryan, Kristin Morris, et al.. (2005). Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. The Journal of Experimental Medicine. 202(11). 1477–1482.
15.
Routes, John M., Kristin Morris, Misoo C. Ellison, & Sharon Ryan. (2004). Macrophages Kill Human Papillomavirus Type 16 E6-Expressing Tumor Cells by Tumor Necrosis Factor Alpha- and Nitric Oxide-Dependent Mechanisms. Journal of Virology. 79(1). 116–123.
16.
Miura, Tanya A., Han Li, Kristin Morris, et al.. (2004). Expression of an E1A/E7 Chimeric Protein Sensitizes Tumor Cells to Killing by Activated Macrophages but Not NK Cells. Journal of Virology. 78(9). 4646–4654.
17.
Miura, Tanya A., Kristin Morris, Sharon Ryan, James L. Cook, & John M. Routes. (2003). Adenovirus E1A, Not Human Papillomavirus E7, Sensitizes Tumor Cells to Lysis by Macrophages Through Nitric Oxide- and TNF-α-Dependent Mechanisms Despite Up-Regulation of 70-kDa Heat Shock Protein. The Journal of Immunology. 170(8). 4119–4126.
18.
Morris, Kristin, et al.. (2003). Role of the NF-κB Signaling Pathway and κBcis-Regulatory Elements on theIRF-1andiNOSPromoter Regions in Mycobacterial Lipoarabinomannan Induction of Nitric Oxide. Infection and Immunity. 71(3). 1442–1452.
19.
Morris, Kristin, et al.. (1993). Increase in Activated T Cells and Reduction in Suppressor/Cytotoxic T Cells in Acute Rheumatic Fever and Active Rheumatic Heart Disease: A Longitudinal Study. The Journal of Infectious Diseases. 167(4). 979–983.
20.
Morris, Kristin, et al.. (1993). Enhancement of IL-1, IL-2 production and IL-2 receptor generation in patients with acute rheumatic fever and active rheumatic heart disease; a prospective study. Clinical & Experimental Immunology. 91(3). 429–436.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Laura Visconti Breakdown of academic impact, for papers by Ulf Alexander Wenzel Breakdown of academic impact, for papers by Marcel Doerflinger Breakdown of academic impact, for papers by Parul Mehra Breakdown of academic impact, for papers by Erin Bailey Breakdown of academic impact, for papers by Yajing Gao Breakdown of academic impact, for papers by Libin Chen Breakdown of academic impact, for papers by Xiaojie Yan Breakdown of academic impact, for papers by Shahzada Khan Breakdown of academic impact, for papers by Diana L. Bonilla